Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Janssen Research & Development, LLC
Hoffmann-La Roche
Bristol-Myers Squibb
Incyte Corporation
Neonc Technologies, Inc.
Tizona Therapeutics, Inc
Incyte Corporation
Sapience Therapeutics
Biotheus Inc.
Celyad Oncology SA